Survey of Ophthalmology
Volume 47, Supplement 1 , Pages S2-S5, August 2002

Changing Paradigms in the Medical Treatment of Glaucoma☆

  • Joern B Soltau, MD

      Affiliations

    • Corresponding Author InformationReprint address: Joern B. Soltau, MD, Kentucky Lions Eye Center, 301 East Muhammed Ali Boulevard, Louisville, KY 40202, USA
    • ,
  • Thom J Zimmerman, MD, PhD

Department of Ophthalmology and Visual Sciences, University of Louisville School of Medicine, Louisville, KY, USA

Abstract 

Glaucoma is defined by a typical optic neuropathy accompanied by characteristic visual field loss and eventual blindness. The major risk factor for glaucoma is elevated intraocular pressure (IOP). Lowering IOP is currently the only proven method for reducing the risk of glaucomatous visual field loss and remains the primary goal of therapy. With the recent introduction of many new medications that lower IOP, the definition of what constitutes maximum tolerated medical therapy has been changing. The treatment can now be tailored better to each individual patient. The regimen needs to be affordable, easy to understand, and least interfering with the patient's quality of life. β-blockers still are the mainstay of initial therapy, but more and more prostaglandin analogs and also α-2 agonists are being used initially. Systemic carbonic anhydrase inhibitors and cholinergics are being used less frequently.

Keywords:  α-2 agonists, β-blockers, carbonic anhydrase inhibitors, glaucoma, medical therapy, prostaglandin analogs

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ Thom J. Zimmerman, MD, PhD, is a consultant and employee of Pharmacia Corp. The authors report no commercial or proprietary interest in any products mentioned or concepts discussed in this article.

PII: S0039-6257(02)00291-6

Survey of Ophthalmology
Volume 47, Supplement 1 , Pages S2-S5, August 2002

Article Tools